F Richards 2nd
Overview
Explore the profile of F Richards 2nd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kilpatrick S, Koplyay P, Ward W, Richards 2nd F
Diagn Cytopathol
. 1998 Jul;
19(1):38-43.
PMID: 9664182
We retrospectively reviewed two fine-needle aspiration biopsy (FNAB) specimens from two patients with histologically confirmed epithelioid hemangioendothelioma (EH). Both patients were men, ages 79 and 39 years; their primary tumors...
2.
Graziano S, Valone F, Herndon 2nd J, Crawford J, Richards 2nd F, Rege V, et al.
Lung Cancer
. 1996 Jun;
14(2-3):315-29.
PMID: 8794413
This Phase II study was designed to determine the efficacy of two chemotherapy regimens with G-CSF support for patients with advanced non-small cell lung cancer (NSCLC). One-hundred and one patients...
3.
Richards 2nd F, Richards C
Semin Roentgenol
. 1996 Apr;
31(2):103-10.
PMID: 8848726
No abstract available.
4.
Atkins J, Muss H, Case L, Richards 2nd F, Grote T, Mcfarland J
Am J Clin Oncol
. 1996 Feb;
19(1):23-5.
PMID: 8554030
We performed a Phase II trial of oral leucovorin and high-dose fluorouracil (5FU) in hormone refractory patients with metastatic prostate cancer who had not had prior chemotherapy. 5FU was given...
5.
Miller A, Herndon 2nd J, Hollis D, Ellerton J, Langleben A, Richards 2nd F, et al.
J Clin Oncol
. 1995 Aug;
13(8):1871-9.
PMID: 7636529
Purpose: This was a randomized phase III study to test the schedule dependency of etoposide given as a conventional 3-day intravenous (IV) regimen versus a prolonged 21-day oral regimen for...
6.
BUSS D, Cashell A, Oconnor M, Richards 2nd F, Case L
Am J Med
. 1994 Mar;
96(3):247-53.
PMID: 8154513
Purpose: To determine the etiology and to evaluate the clinical consequences of an extremely elevated platelet count. Patients And Methods: A review of the medical records was performed on all...
7.
Graziano S, Herndon 2nd J, Richards 2nd F, DiFino S, Modeas C, Duggan D, et al.
Cancer
. 1993 Jul;
72(1):62-8.
PMID: 8389667
Background: This Phase I study was designed to determine the maximum tolerated dose of ifosfamide-mesna with a fixed dose of cisplatin without growth factor or hematopoietic precursor support. Methods: Twenty-five...
8.
Cruz J, Case L, Dalton H, Ramseur W, Richards 2nd F, Jackson D, et al.
Invest New Drugs
. 1992 Apr;
10(1):35-7.
PMID: 1535064
Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after...
9.
Muss H, Case L, Richards 2nd F, White D, Cooper M, Cruz J, et al.
N Engl J Med
. 1991 Nov;
325(19):1342-8.
PMID: 1922236
Background: Chemotherapy for metastatic breast cancer is palliative, and the optimal duration of therapy is unknown. We designed a trial to determine whether continuous treatment is superior to stopping treatment...
10.
Muss H, Cooper M, Brockschmidt J, Ferree C, Richards 2nd F, White D, et al.
Breast Cancer Res Treat
. 1991 Oct;
19(2):77-84.
PMID: 1756271
158 evaluable patients with stage II, lymph node positive, carcinoma of the breast were randomized to adjuvant therapy with either melphalan (L-PAM) or cyclophosphamide, methotrexate, and fluorouracil (CMF) after mastectomy....